Therapeutics : IROFULVENS AGAINST MULTI-DRUG RESISTANCE CANCERS
Many cancers develop resistance to chemotheraputic drugs and is a major factor in the failure against multiple cancers. Chemotherapeutic drugs do not act against higher proportion of drug-resistant cells. As the tumor begins to grow again especially in late stage metastatic cancers, chemotherapeutic drugs may fail because of this drug resistance. Irofulvens are novel class of transcription coupled repair mechanism (TCR) inhibitors and are shown to act against multiple drug resistant mechanisms. This class of drugs have shown positive outcome in previous human clinical trials. Lantern will continue to advance this unique class of drugs against hard to treat multi-drug resistance cancers.